In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Yuhan Corporation

http://eng.yuhan.co.kr/Main/

Latest From Yuhan Corporation

New Korea Vaccine Funds Eye Broad Industry Benefits, Partnerships

Yuanta Investment, which will launch one of two major new public/private biopharma support funds in South Korea later this year, talks about the strategy behind the initiative and the plans for diverse collaborations with pharma companies both at home and abroad.

South Korea Financing

The Hunt For Big Fish: How KDDF Is Helping Create Korean Deals

Korea Drug Development Fund CEO H. Samuel Muk talks to Scrip how the government agency has evolved to support the Korean biopharma industry’s R&D and business development activities, as well as what key new projects are underway.

South Korea Deals

Korea’s Key Words For 2023: Regulatory Innovation, Digital Healthcare

The Pink Sheet’s roundup of key regulatory issues in Korea for 2022 and outlook for this year.

South Korea Pink Sheet Perspectives

Will The Dark Tunnel For Korean Biopharmas End In 2023?

Scrip wraps up major R&D and corporate developments for Korean biopharmas in 2022 and outlines what lies ahead for them in the new year.

Commercial South Korea
See All

Company Information

  • Industry
  • Distributors
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • Yuhan USA
UsernamePublicRestriction

Register